Ivermectin Medical Valley

Ivermectin, the active ingredient in Ivermectin Medical Valley, is an anthelmintic (macrocyclic lactone) presented as an oral tablet for oral use. It treats a range of parasitic infections in humans, including onchocerciasis, strongyloidiasis, lymphatic filariasis, scabies and pediculosis.

GNH USA supplies Ivermectin Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an anthelmintic that targets parasitic helminths and ectoparasites.

- Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eradicates intestinal Strongyloides stercoralis infection. - Lymphatic filariasis: eliminates adult worms and microfilariae to interrupt transmission. - Scabies: kills Sarcoptes scabiei mites, relieving itching and skin lesions. - Pediculosis: eliminates head lice infestations.

Ivermectin may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Dizziness: transient light‑headedness. - Pruritus: skin itching.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction. - Hepatotoxicity: elevated liver enzymes or liver injury. - Neurologic toxicity: seizures, ataxia, or altered consciousness. - Severe hypotension: sudden drop in blood pressure.

When prescribing ivermectin, consider the following precautions.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; consider risk vs benefit. - Concomitant CNS depressants: may enhance neurotoxicity. - Liver impairment: use with caution; monitor hepatic function. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Ivermectin can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivermectin exposure. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): may increase ivermectin levels and risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as ivermectin may affect clotting. - Other antiparasitics (e.g., albendazole): assess additive toxicity. - CNS active drugs (e.g., benzodiazepines): observe for enhanced sedation.